Advertisements

Paracetamol Mylan

Quick links to important sections

Paracetamol Mylan

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Paracetamol Mylan

Paracetamol Mylan is a medicine containing the active substance paracetamol, which is the International Nonproprietary Name (INN) for the widely recognized compound also known as acetaminophen in regions like the United States and Canada. It is a foundational medication used globally for its primary actions as an analgesic (pain reliever) and antipyretic (fever reducer).

Property Description
Active Ingredient Paracetamol (Acetaminophen)
Manufacturer/Origin Mylan (now Viatris, a global generic company)
Pharmacological Class Non-opioid Analgesic, Antipyretic
Typical Availability Over-The-Counter (OTC)
Primary Forms Tablets, Oral Solutions, Suppositories

As a generic version manufactured by Mylan (now Viatris), this medicine offers the same established therapeutic effects as original brand-name products, utilizing the identical active ingredient. Paracetamol is chemically classified as a p-aminophenol derivative, a distinction that is clinically recognized for its effectiveness and suitability for patients who may not tolerate nonsteroidal anti-inflammatory drugs (NSAIDs).

Paracetamol is classified as a first-line therapy supported by pharmacological evidence for managing mild to moderate pain and fever. Paracetamol Mylan is available in various formulations, including common 500 mg oral tablets and specific oral solutions aimed at providing accurate, weight-based dosing for pediatric patients. It is vital to note that while the medicine is effective and generally safe at recommended doses, strict adherence to the maximum daily amount is required, as exceeding this limit is the most common cause of drug-induced liver injury worldwide.

Regulatory References

  1. MedlinePlus Drug Information
Advertisements

What side effects are possible with Paracetamol Mylan?

Possible Side Effects and Safety Information

This section describes adverse reactions and safety restrictions for Paracetamol Mylan as documented in official government regulatory documents.

Frequency-Classified Adverse Reactions

Regulatory documents classify side effects by their documented frequency in clinical use:

Classification Examples of Reactions
Rare (1 in 1,000 to 1 in 10,000 patients) Various blood disorders including thrombocytopenia and leukopenia; hypotension (low blood pressure); liver dysfunction; allergic reactions such as swelling (angioedema).
Very Rare (Fewer than 1 in 10,000 patients) Hypersensitivity reactions leading to anaphylactic shock; severe skin reactions including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP).
Frequency Not Known Certain blood disorders (agranulocytosis, neutropenia, pancytopenia); asthma-like breathing difficulties in sensitive individuals.

Serious and Clinically Significant Risks

Acute liver failure is documented as a serious, dose-related adverse reaction, especially in cases of overdose. Other severe documented reactions include life-threatening severe cutaneous adverse reactions (SCARs) and anaphylactic shock.

Safety Restrictions and Population Considerations

Use of this medicine requires particular caution in individuals with pre-existing conditions that can increase risk, including impaired liver function or severe kidney impairment. Caution is also documented for patients who have chronic alcoholism, chronic malnutrition, or dehydration, and in those weighing less than 50 kg. The safety profile notes the potential for increased risk when used concurrently with other medicines that affect the liver.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for paracetamol overdose emphasizes the primary, dose-dependent risk of acute liver failure (hepatotoxicity), which can escalate to hepatic encephalopathy and potentially result in the need for a liver transplant or death.

Clinical Overdose Manifestations Severe Outcomes and Actions
Early Signs: Nausea, vomiting, pallor, and anorexia are documented initial symptoms, often within the first 24 hours. Severe Outcomes: Acute liver failure, acute kidney injury, cerebral oedema, and metabolic acidosis are officially listed complications.
Delayed Signs: Abdominal pain, jaundice, and elevated liver transaminases (ALT/AST) develop as toxicity progresses. Required Action: The regulator mandates immediate medical advice must be sought and the patient urgently referred to a hospital or Poison Control Center.

The crucial regulatory instruction is that medical help must be secured immediately, even if the affected person feels well or displays no obvious symptoms. This mandate is based on the time-sensitive nature of the toxicity, which dictates the effectiveness of the specific antidote, N-acetylcysteine (NAC).

Official labeling identifies specific patient populations at increased risk, including individuals with chronic alcohol abuse, chronic malnutrition, or pre-existing severe hepatic or renal impairment. Treatment protocols require clinical monitoring, including measurement of plasma paracetamol concentration.

Advertisements

Therapeutic Uses of Paracetamol Mylan

Quick Facts

  • May support the management of: Mild to moderate pain.
  • May help address: High body temperature (fever).

Paracetamol Mylan is an established medication used to support the management of certain common symptoms. Its primary function is to serve as an analgesic (pain reliever) and an antipyretic (fever reducer).

The medication may help provide relief from common types of mild to moderate pain. This may include, but is not limited to, temporary pain associated with headaches, muscle aches, toothaches, and menstrual discomfort. In addition to addressing pain, the drug may also contribute to the temporary lowering of a high body temperature (fever) that may accompany colds, flu, or other common conditions.

The use of this drug is widely accepted in clinical practice for these therapeutic domains.

It is important that any use of this medication is aligned with a patient's individual health status and the advice of a healthcare provider.

Regulatory References

  1. NIH MedlinePlus guidance
Advertisements

Eligibility and Restrictions for Use

Paracetamol Mylan is an over-the-counter medicine for which official regulatory documents define clear eligibility and non-eligibility profiles based on patient characteristics and clinical conditions.

Populations That Must Not Use This Medicine (Contraindications)

  • Hypersensitivity: Individuals with a known allergy or severe hypersensitivity reaction to paracetamol or any of the product's excipients must not use this medicine.
  • Severe Organ Impairment: It is strictly contraindicated in patients with severe hepatic (liver) failure.

Populations With Restricted or Cautioned Use

  • Concomitant Paracetamol Use: The medicine must not be taken with any other product containing paracetamol (acetaminophen) due to the high risk of liver damage from accidental overdose.
  • Hepatic and Renal Impairment: Patients with mild-to-moderate liver or severe kidney impairment require special caution, and a reduced daily dose is often necessary.
  • Chronic Alcoholism: Caution is advised, as the hazard of liver damage is greater in those with non-cirrhotic alcoholic liver disease or chronic, excessive alcohol consumption.
  • Pediatric Population: The use of standard adult-strength tablets/capsules is typically not recommended for children below a specific age or body weight, such as those under 10 or 12 years of age, or under 50 kg body weight, due to the risk of accidental overdose.
  • Pregnancy and Lactation: Paracetamol may be used during pregnancy if clinically needed but must be taken at the lowest effective dose for the shortest possible duration. It is generally considered compatible with breastfeeding.
Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for paracetamol (the active substance in Paracetamol Mylan) details several documented interaction patterns with other medicinal products and substances. These interactions are categorized by their effect on drug exposure and pharmacodynamic outcomes.

Documented Drug-Drug Interactions

Co-administration with warfarin and other oral anticoagulants results in a pharmacodynamic interaction that officially increases the risk of bleeding, particularly when paracetamol is taken chronically at higher doses. Pharmacokinetic interactions also occur: Probenecid reduces paracetamol clearance, resulting in a significant increase in paracetamol plasma concentrations. Conversely, enzyme-inducing medicines, such as rifampicin or phenytoin, are documented to accelerate paracetamol metabolism, which may reduce its therapeutic exposure.

Timing and Absorption Constraints

A specific administration constraint exists for the drug cholestyramine, which reduces paracetamol absorption. Regulatory information requires that cholestyramine be administered at least one hour after paracetamol to minimize the interference with absorption. Co-administration with food is noted to delay the time to peak concentration ( T max) of paracetamol but does not significantly affect the total absorbed amount.

Population and Substance-Specific Risks

The combination of paracetamol with chronic alcohol use is officially documented as significantly increasing the risk of hepatotoxicity (liver damage). This risk is noted to be heightened in the patient population with pre-existing hepatic impairment. The regulatory profile also notes that co-administration may affect the plasma levels of other medicines, such as chloramphenicol.

Advertisements

Mechanism of Action

Paracetamol Mylan exerts its action primarily within the central nervous system (CNS) through multiple, interconnected mechanistic domains. The primary domain involves the drug’s interaction with the cyclooxygenase (COX) enzyme system in the brain and spinal cord. Paracetamol selectively modulates the peroxidase function of these enzymes, leading to the suppression of prostaglandin (PG) synthesis in the CNS. This action influences molecular steps within pathways regulating central thermal and sensory responses.

A secondary mechanistic cascade involves the drug's active metabolite, which engages receptors in the endocannabinoid and descending inhibitory serotonergic pathways. This metabolite interacts with molecules, including the transient receptor potential vanilloid 1 (TRPV1) channel and cannabinoid receptor 1 (CB1). This engagement initiates or suppresses specific signaling sequences, thereby modifying activity involved in central nociceptive processing and decreasing the downstream effect of heightened signaling molecule activity.

Advertisements

Dosage and Administration Information

Administration Routes and Standard Dosing

Paracetamol Mylan is administered according to standard principles governing its dosage, frequency, and route. The substance is primarily approved for Oral use (tablets and solutions) and Rectal use (suppositories). The Intravenous route is also approved for the active substance in a clinical setting. The standard single dose for adults typically ranges from 500 mg to 1000 mg (1 g).


Frequency and Administration Context

A minimum interval of 4 hours must separate each administration, with the maximum total daily intake not exceeding 4000 mg in a 24-hour period. The medicine can be taken with or without food. Specific preparations require attention: liquid forms must be accurately measured using the provided dosing device, and extended-release tablets must not be crushed or chewed to preserve their controlled release profile.


Population-Specific Rules and Duration

For certain populations, dose adjustments are mandated. Pediatric dosing is based on body weight (10 to 15 mg/kg per dose). Patients with renal or hepatic impairment may require a reduced maximum daily dose (e.g., 2000 mg) or an extended dosing interval. Usage is restricted to short-term intermittent periods, and administration should not be combined with other paracetamol-containing products.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Initial Research Focus

Initial research focused on how Paracetamol’s compound affects specific central nervous system pathways that are associated with the perception of pain and the regulation of body temperature. This foundational work was largely conducted in in vitro and animal models to characterize the basic biological effects of the compound.


Core Efficacy Trials

A large-scale, multi-center, randomized controlled trial (RCT) evaluated whether treatment with the active ingredient had an effect on reducing headache frequency over a defined period. The primary endpoint was an average change in self-reported pain scores, with observed results consistent with the study hypothesis.

  • The study also examined the observation of pain levels in participants receiving the compound versus those receiving a placebo.
  • Secondary analyses investigated the effect on patient-reported quality of life metrics, with results noting an observation of change in daily functioning during periods of acute pain.

Tolerability in Research Trials

Data regarding participant tolerability across several Phase III trials were pooled for review. A sub-group analysis examined the drug’s tolerability in elderly patients, and the study found no new adverse events specific to this population.

Limitations and Patient Exclusions

Research has explored this treatment as an option for common pain and fever. Findings noted that individuals with a history of severe allergies to paracetamol were excluded from the study population, as were individuals with significant pre-existing liver conditions. Evidence regarding effects in these highly excluded groups remains limited, and studies did not evaluate adjustment of existing medication regimens.

Key Studies & References

  1. Tricyclic antidepressants, venlafaxine and paracetamol for acute low back pain: a network meta-analysis
  2. Paracetamol for acute lower back pain
  3. Clinical Guideline: Management of fever in young children (NICE)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Paracetamol Mylan (FAQ)


Q: Is Paracetamol Mylan the same as just 'paracetamol'?

Paracetamol Mylan is a medicine that contains the established active substance paracetamol (also known as acetaminophen). The name 'Mylan' indicates the company that produces this specific generic version. According to official principles, this product provides the same active ingredient and established therapeutic effects as other medicines containing paracetamol.


Q: What is the difference between Paracetamol Mylan and other brands of paracetamol?

Paracetamol Mylan is defined as a generic version, meaning it is therapeutically equivalent to original brand-name products, containing the identical active ingredient. Differences typically relate only to the manufacturer (Mylan/Viatris) and the inactive ingredients (excipients) used in the specific formulation.


Q: How long after taking it should I expect Paracetamol Mylan to start working?

Regulatory-based patient information describes the onset of pain relief or fever reduction as typically occurring within 30 minutes to one hour after administration. Official sources note that taking the medicine with food may delay the time it takes to reach the maximum concentration in the body.


Q: How long does the effect of Paracetamol Mylan typically last?

The therapeutic effect of paracetamol is generally considered to last for four to six hours. Official dosing instructions require that a minimum interval of at least four hours separates each administration.


Q: What are the regulatory conditions for using Paracetamol Mylan during pregnancy?

Official guidance states that paracetamol may be used during pregnancy only if there is a clear clinical need. Official documentation describes the required use conditions as being the lowest effective dose for the shortest possible duration and frequency, in line with established clinical guidance.


Q: What does regulatory information state about using Paracetamol Mylan while breastfeeding?

According to official regulatory and medical resources, paracetamol is generally considered compatible with breastfeeding when used at the recommended doses and for the specified duration.


Q: Can Paracetamol Mylan cause issues with my liver?

Regulatory documents state that paracetamol can cause serious liver damage (hepatotoxicity), especially when taken in an overdose. Caution is specifically advised for patients with pre-existing impaired liver function or chronic, excessive alcohol use, as these conditions are documented to increase the risk of liver issues.


Q: Can children take Paracetamol Mylan?

Paracetamol products are suitable for children, but official guidance is that dosing is strictly based on the child's body weight. Regulatory notes indicate that standard adult-strength tablets are typically not recommended for children under a specific age or weight due to the risk of accidental overdose.


Q: Does taking Paracetamol Mylan make you sleepy?

Official adverse reaction reports for paracetamol alone do not commonly list drowsiness (somnolence) as an expected or frequent side effect. The regulatory profile does not classify paracetamol as a sedative medicine.


Q: Does the 'Mylan' part of the name mean anything important?

The name 'Mylan' identifies the company (now Viatris) that manufactures and markets this particular formulation. This name serves to distinguish this generic product from other paracetamol brands.


Q: What happens if I take Paracetamol Mylan for a long period of time?

Official documentation restricts the use of paracetamol to short-term intermittent periods. Prolonged or frequent use is noted to be discouraged in official documentation, as it is associated with potential long-term risks, including kidney damage and an increased risk of bleeding when combined with certain anticoagulants.


Q: What does regulatory information state about using Paracetamol Mylan with kidney impairment?

Use of this medicine requires caution in individuals with severe kidney impairment. Official principles state that a reduced daily dose or an extended time interval between doses may be necessary for patients with renal issues.


Q: Is headache listed as a possible side effect of Paracetamol Mylan?

While paracetamol is primarily used to relieve headaches, regulatory adverse event listings in clinical trials occasionally include headache as a documented reaction. This reaction is generally noted in the drug's safety profile, often categorized by specific formulations.


Q: Are there specific vitamins or supplements that interact with Paracetamol Mylan?

Official drug labels list specific drug-drug interactions (such as with warfarin or probenecid) but typically do not provide a complete list of every possible vitamin or supplement interaction. General medical guidance advises informing a healthcare professional of all concomitant products.


Q: Does Paracetamol Mylan interact with herbal remedies like St. John's Wort?

Specific herbal remedies like St. John's Wort are generally not explicitly detailed in the interaction sections of regulatory documents for paracetamol. However, the label does warn that enzyme-inducing medicines may accelerate paracetamol metabolism, which is a known property of some herbal products.


Q: What is the difference in purpose between Paracetamol Mylan and Ibuprofen?

Paracetamol Mylan (paracetamol) is officially defined as an analgesic (pain reliever) and antipyretic (fever reducer) that acts mainly in the central nervous system. Ibuprofen is defined as a Nonsteroidal Anti-Inflammatory Drug (NSAID) that acts by reducing inflammation, in addition to its effects on pain and fever.


Q: Are there any food restrictions when using Paracetamol Mylan?

The official product information indicates that the medicine can generally be taken with or without food. It is noted, however, that co-administration with food may delay the time it takes to reach peak concentration in the bloodstream.


Q: How does Paracetamol Mylan work to reduce a high temperature?

Paracetamol works to reduce fever (its antipyretic action) by modulating the activity of the cyclooxygenase (COX) enzyme system in the central nervous system. This action suppresses the formation of certain prostaglandins that are key in regulating the body's internal temperature.


Q: Is Paracetamol Mylan habit-forming or addictive?

Paracetamol, the active substance, is generally not classified as a controlled substance and is categorized as a non-opioid analgesic. It is not associated with the typical dependence or physical addiction potential seen with opioid pain medications.


Q: Why is Paracetamol Mylan sometimes noted as a suitable choice over other pain relievers?

Official sources note that paracetamol is a first-line therapy recognized for its suitability for patients who may not tolerate Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This includes individuals who may have conditions like certain gastrointestinal issues or those with an increased risk of bleeding.


Q: Can Paracetamol Mylan affect blood pressure?

Official regulatory documents list hypotension (low blood pressure) as a rare adverse reaction to paracetamol. The primary safety profile does not specify a general, common effect on raising blood pressure at standard doses.


Q: Is Paracetamol Mylan a controlled substance?

The active ingredient, paracetamol, is not classified as a controlled substance under major national and international regulatory scheduling systems.


Q: Why do some people experience stomach upset with paracetamol products?

Regulatory adverse event data for paracetamol products occasionally list certain gastrointestinal reactions in clinical use. These can include nausea, vomiting, or abdominal pain, which are noted as documented side effects particularly in some formulations.

Advertisements

How should Paracetamol Mylan be stored and disposed of?

The official regulatory documents specify strict conditions for storing and disposing of Paracetamol Mylan to maintain product quality and protect the environment.

Scope Area Official Regulatory Requirement
Storage Temperature Must be stored below 25 C.
Protection Requirements Must be stored to protect it from light and moisture.
Container Requirements Must be stored in the original container/package and kept tightly closed.
Child Safety Must be kept out of the sight and reach of children.
Disposal Mandate Must not be disposed of via wastewater or household waste. The pharmacist must be asked for proper disposal to help protect the environment.

The medicine should not be used after the expiry date (EXP) stated on the packaging. These constraints ensure the stability of the product and compliance with mandatory pharmaceutical waste handling procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paracetamol Mylan found in:

A-Z Index: